Business
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-C in Statin Intolerant Adults – ANN ARBOR, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from a Phase 2 study of bempedoic acid in children, along with an additional post hoc analysis from CLEAR Outcomes describing patient traits associat
About this update from Esperion Therapeutics, Inc.
[{"type":"image","alt":"Esperion Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Esperion Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/4890074d6b0f0d0a38002f9d11a84e21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.RjG9ikKgzqPj9dUWUz0AQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/4890074d6b0f0d0a38002f9d11a84e21","width":300,"height":94},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/.RjG9ikKgzqPj9dUWUz0AQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/4890074d6b0f0d0a38002f9d11a84e21","width":300,"height":94}},"lazy":false},{"type":"text","content":"– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years –","length":83,"tagName":"p"},{"type":"text","content":"– A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-C in Statin Intolerant Adults –","length":147,"tagName":"p"},{"type":"text","content":"ANN ARBOR, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from a Phase 2 study of bempedoic acid in children, along with an additional post hoc analysis from CLEAR Outcomes describing patient traits associated an enhanced LDL-C lowering with bempedoic acid. These data were presented as moderated Science at a Glance sessions at the European Atherosclerosis Society (EAS) Congress 2026 taking place on May 24-27, 2026, in Athens, Greece.","length":498,"tagName":"p"},{"type":"text","content":"“The data from CLEAR Path 1 in pediatric patients with familial hypercholesterolemia gives promise for bempedoic acid as a potentially safe and effective additional lipid lowering agent for use in children who carry a greater lifetime cardiovascular risk and will further inform Phase 3 studies,” said Christie M Ballantyne, MD, Professor of Medicine and Chief of Cardiology and Cardiovascular Research at Baylor College of Medicine and member of the Esperion Pediatric Study Steering Committee. “The 30% or greater reduction in LDL-C more often observed in women, those with higher baseline LDL-C, and with concurrent baseline ezetimibe use as seen in the post-hoc analysis of CLEAR Outcomes confirms what was prev...